IN THE UNITED STATES PATENT AND TRADEMARK OFFICE **Ehud GAZIT** 10/562,852 Serial No.: Filed: April 19, 2006 PEPTIDES ANTIBODIES DIRECTED For: THEREAGAINST AND METHODS USING SAME FOR DIAGNOSING AND TREATING AMYLOID-

ASSOCIATED DISEASES

Group Art Unit:

Attorney Docket: 31230

Examiner:

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

The undersigned states:

any communica	t each item of information contained in the information disclosure statement was first cited in tion from a foreign patent office in a counterpart foreign application not more than three monthing of the information disclosure statement; or
communication person signing to information dis-	at no item of information contained in the information disclosure statement was cited in a from a foreign patent office in a counterpart foreign application, and, to the knowledge of the the certification after making reasonable inquiry, no item of information contained in the closure statement was known to any individual designated in 37 CFR 1.56(c) than three months ng of the information disclosure statement.
П	Please charge the fee set forth in 37 CFR 1.17 (p) to Deposit Account 501407.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin I. Majorhan

Martin D. Moynihan Registration No. 40,338

Dated: July 15, 2008